Stockscreener 앱 받기
8.41
3.89%
-0.34
시간 외 거래:
8.83
0.42
+4.99%
전일 마감가:
$8.75
열려 있는:
$8.5
하루 거래량:
14,570
Relative Volume:
0.45
시가총액:
$30.98M
수익:
-
순이익/손실:
$-24.77M
주가수익비율:
-11.52
EPS:
-0.73
순현금흐름:
$-17.36M
1주 성능:
-6.87%
1개월 성능:
+3.83%
6개월 성능:
+17.28%
1년 성능:
-37.24%
1일 변동 폭
$7.80
$8.65
1주일 범위
$7.80
$9.67
52주 변동 폭
$4.5601
$19.00
Mink Therapeutics Inc Stock (INKT) Company Profile
명칭
Mink Therapeutics Inc
전화
212-994-8250
주소
149 FIFTH AVENUE, NEW YORK
INKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
8.41 | 30.98M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Mink Therapeutics Inc 주식(INKT)의 최신 뉴스
Where are the Opportunities in (INKT) - news.stocktradersdaily.com
HC Wainwright Issues Negative Forecast for INKT Earnings - The AM Reporter
What is William Blair’s Forecast for INKT Q1 Earnings? - Defense World
What is William Blair’s Estimate for INKT Q1 Earnings? - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2024 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics (NASDAQ:INKT) Given Buy Rating at HC Wainwright - Defense World
MiNK Therapeutics Inc (INKT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports 2024 Progress and Financials - TipRanks
MiNK Therapeutics’ Earnings Call Highlights Strategic Gains - TipRanks
MiNK Therapeutics, Inc. SEC 10-K Report - TradingView
Earnings call transcript: Mink Therapeutics Q4 2024 reports reduced net loss - Investing.com
Mink Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress - GlobeNewswire
MiNK Therapeutics Reports 2024 Financial Results and Highlights Clinical Advancements in iNKT Cell Therapies - Nasdaq
MiNK Therapeutics reports Q4 EPS (62c), consensus (50c) - TipRanks
Earnings Scheduled For March 18, 2025 - Benzinga
(INKT) Technical Pivots with Risk Controls - Stock Traders Daily
Mink Therapeutics Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
MiNK Therapeutics (INKT) Projected to Post Earnings on Tuesday - Defense World
New Strong Buy Stocks for July 11th - MSN
The Future of Refractory Multiple Myeloma Therapy: 75+ - openPR
MiNK Therapeutics, Inc. to Announce Fourth Quarter and Year End 2024 Financial Results on March 18th - Nasdaq
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report - GlobeNewswire
When Will MiNK Therapeutics Reveal Its 2024 Financial Performance? - StockTitan
What is HC Wainwright’s Estimate for INKT Q1 Earnings? - Defense World
Brokers Set Expectations for INKT FY2029 Earnings - Defense World
MiNK Therapeutics stock target soars to $35 at H.C. Wainwright By Investing.com - Investing.com South Africa
MiNK Therapeutics stock target soars to $35 at H.C. Wainwright - Investing.com India
MiNK Therapeutics presents allo-iNKTs combination data in 2L gastric cancer - TipRanks
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs - GlobeNewswire
MiNK Therapeutics Presents Promising Data from Phase 2 Study of Allo-iNKT Cell Therapy AgenT-797 at AACR Meeting - Nasdaq
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting - The Manila Times
Can This Novel Cancer Therapy Revolutionize Gastric Cancer Treatment? New Clinical Data Reveals Answer - StockTitan
How the (INKT) price action is used to our Advantage - news.stocktradersdaily.com
MiNK Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Nigeria
MiNK Therapeutics Announces Regained Compliance With Nasdaq Listing Requirements - Nasdaq
MiNK Therapeutics regains Nasdaq compliance - Investing.com India
Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences - The Manila Times
MiNK Therapeutics Regains Compliance with Nasdaq Listing Requirements - Nasdaq
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements - GlobeNewswire
Can MiNK Therapeutics' Nasdaq Compliance Victory Signal a Turnaround for iNKT Cell Therapy Pioneer? - StockTitan
Stocks Surge Across Health Services and Industry Sectors: Nuvve, Exagen, and Flexsteel Lead the Way - HPBL
Mink Therapeutics Inc (INKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10.70%
자본화:
|
볼륨(24시간):